Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Leadership Strategy Executive Changes

Hudson To Succeed Brandicourt As Sanofi CEO

Executive Summary

All change at the top for Sanofi which has poached Novartis pharma chief Paul Hudson to succeed Olivier Brandicourt as CEO.

You may also be interested in...



Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform

As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme. 

Novartis Q2 Preview: All Eyes On New Launches

The Basel-headquartered company has launched three high-profile drugs in the past couple of months. Analysts are waiting to see what initial impact these potential future growth drivers are having.

The Challenges Facing Paul Hudson At the Helm of Sanofi

Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.

Table

View full table

Topics

Related Companies

Tags:
Leadership Strategy Executive Changes
Latest Headlines

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

Pipeline Watch: Five Approvals And 23 Phase III Updates

Metsera Launches As New Obesity Contender Flush With $290m

See All
UsernamePublicRestriction

Register

SC125354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By